Arthritis & Rheumatism, Volume 63,
November 2011 Abstract Supplement

Abstracts of the American College of
Rheumatology/Association of Rheumatology Health Professionals
Annual Scientific Meeting
Chicago, Illinois November 4-9, 2011.


The Presence of HLA-B15 Determines the Clinical Presentation and Outcome in Colombian's Patients with Spondyloarthropathies.

Londono1,  John, Pena2,  Paola, Santos3,  Ana, Bautista-Molano2,  Wilson, Sanchez2,  Consuelo Romero, Avila4,  Mabel, Porras4,  Marlon

Universidad de La Sabana, Chía, Colombia
Spondyloarthritis Group. Rheumatology Division. Hospital Militar Central/Universidad de La Sabana. Bogotá. Colombia, Bogotá, Colombia
Universidad de Los Andes, Bogota, Colombia
Spondyloarthritis Group. Rheumatology Division. Hospital Militar Central/Universidad de La Sabana. Bogotá. Colombia, Bogota, Colombia
Instituto Nacional de Cardiologia Ignacio Chavez, Ciudad de Mexico DF, Mexico
Spondyloarthritis Group. Rheumatology Division. Hospital Militar Central/Universidad de La Sabana, Bogotá, Colombia

Background/Purpose:

In patients with Spondyloarthropathies (SpA) the association with the HLA-B15 has been previously established: 35/228 patients were positive for this allele, while only was present in 2/100 controls: OR 5.3CI95%: 1.8–17.6. (EULAR2011–4847).To determine differences in clinical presentation and outcomes of the disease among HLA-B15+, HLA-B27+ and non B27-B15 patients.

Methods:

435 of a total of 574 patients with SpA according to ESSG classification criteria and had completed HLA typing were selected. Comparisons with HLA-B27+, B15 and non B27-B15 were made to the main clinical features; disease-related background and the commitment level of the sacroiliac joints.

Results:

The main findings are presented in the table:

VARIABLEHLA-B15(+) n=52HLA-B27(+) n=179OTHER HLA-B n=203
Age (y)31.8 ± 10.634.9 ± 10.135.5 ± 13.03
Age of onset (y)26.9 ± 9.227.3 ± 10.429.2 ± 10.6
Evolution (y)4.7 ± 5.2*7.9 ± 10.36.4 ± 8.6
Sex(M/F)33/19 1.7:1*145/34 4.2:1128/76 1.6:1
u-SpA25 (48.1%)*35 (19.6%)102 (50.2%)
AS10 (19.2%)92 (51.4%)*43 (21.2%)
ReA17 (32.7%)*51 (28.5%)47 (23.2%)
PsA0 (0%)1 (0.1%)11 (5.4%)
Family history for SpA5 (9.6%)*10 (5.6%)12 (5.9%)
Inflammatory back pain11 (21.1%)50 (27.9%)60 (29.5%)
SCHOBER15.4 ± 3.714.7 ± 2.914.7 ± 2.1
X-ray Sacroilitis <II26 (50%)*51 (28.6%)151 (74.4%)
X-ray Sacroilitis >=II26 (50%)128 (71.4%)*52 (25.6%)
Occiput to wall distance (cm)0.2 ± 1.41.3 ± 3.50.5 ± 1.7
ASAS Axial criteria36 (69.2%)178 (99.4%)*84 (41.4%)
ASAS Peripheral criteria41 (78.8%)161 (89.9%)203 (100%)

Conclusion:

Patients HLA-B15 positive initiated the disease at an earlier age and had a shorter time of evolution, the predominance of males was lower, with a greater proportion of patients with u-SpA and a lower degree of compromise of sacroiliacs joint. This seems to be a pattern of presentation of the disease.

To cite this abstract, please use the following information:
Londono, John, Pena, Paola, Santos, Ana, Bautista-Molano, Wilson, Sanchez, Consuelo Romero, Avila, Mabel, et al; The Presence of HLA-B15 Determines the Clinical Presentation and Outcome in Colombian's Patients with Spondyloarthropathies. [abstract]. Arthritis Rheum 2011;63 Suppl 10 :542
DOI:

Abstract Supplement

Meeting Menu

2011 ACR/ARHP